The hunter syndrome treatment market is expected to grow from an estimated USD 861.5 million in 2024 to USD 1480.4 million in 2033, at a CAGR of 6.20%. Hunter syndrome, also known as mucopolysaccharidosis II, MPS II, is a rare genetic disorder caused by mutations in the IDS gene. The mutations result in a deficiency of the enzyme iduronate-2-sulfatase. This deficiency causes glycosaminoglycans,...